MedTrace Logo

Role of Placenta Growth Factor in Sickle Acute Chest Syndrome

NCT00448370 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 136

Last updated 2017-12-21

No results posted yet for this study

Summary

The purpose of this research study is to find out whether Placenta Growth Factor (PlGF) and related tests can predict the development of acute chest syndrome (ACS) in patients with sickle cell disease (SCD) during a period where patients are well and during admission to the hospital for an acute sickle event to see if these measures can predict the development of ACS. Understanding events precipitating ACS may lead to preventative and interventional therapies which will improve patient outcomes and quality of life.

Conditions

  • Anemia, Sickle Cell

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Children's Hospital Medical Center, Cincinnati

    lead OTHER

Principal Investigators

  • Karen Kalinyak, MD · Children's Hospital Medical Center, Cincinnati

  • Punam Malik, MD · Children's Hospital Medical Center, Cincinnati

Eligibility

Min Age
66 Months
Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00448370 on ClinicalTrials.gov